HSP90 inhibitor 17-AAG suppresses the proliferation of FLT3-ITD/D835 mutant AML cells

被引：0
|
作者：
Katayama, Kazuhiro [1 ]
Noguchi, Kohji [1 ]
Sugimoto, Yoshikazu [1 ]
机构：
[1] Keio Univ, Fac Pharm, Div Chemother, Tokyo, Japan
来源：
CANCER SCIENCE | 2018年 / 109卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
J-1015
引用
收藏
页码：294 / 294
页数：1
相关论文
共 50 条
  • [1] Effects of the HSP90 inhibitor 17-AAG in glioblastoma multiforme
    Sauvageot, C.
    Barnes, J.
    Weatherbee, J.
    Ramakrishna, N.
    Kesari, S.
    Stiles, C.
    Kieran, M.
    Wen, P.
    NEURO-ONCOLOGY, 2006, 8 (04) : 417 - 417
  • [2] 17-AAG, an Hsp90 inhibitor, causes kinetochore defects: a novel mechanism by which 17-AAG inhibits cell proliferation
    Y Niikura
    S Ohta
    K J Vandenbeldt
    R Abdulle
    B F McEwen
    K Kitagawa
    Oncogene, 2006, 25 : 4133 - 4146
  • [3] HSP90 Inhibitor 17-AAG Selectively Eradicates Lymphoma Stem Cells
    Newman, Bryan
    Liu, Yan
    Lee, Hsiu-Fang
    Sun, Duxin
    Wang, Yin
    CANCER RESEARCH, 2012, 72 (17) : 4551 - 4561
  • [4] 17-AAG, an Hsp90 inhibitor, causes kinetochore defects: a novel mechanism by which 17-AAG inhibits cell proliferation
    Niikura, Y.
    Ohta, S.
    Vandenbeldt, K. J.
    Abdulle, R.
    McEwen, B. F.
    Kitagawa, K.
    ONCOGENE, 2006, 25 (30) : 4133 - 4146
  • [5] 17-AAG, an inhibitor of HSP90, suppresses cellular growth of mesothelioma cell lines in vitro
    Korfee, S.
    Gauler, T.
    Nishio, K.
    Arao, T.
    Saijo, N.
    Cortes-Incio, D.
    Pottgen, C.
    Krbek, T.
    Seeber, S.
    Eberhardt, W. E. E.
    LUNG CANCER, 2006, 54 : S54 - S54
  • [6] Alleviating neurodegeneration by an anticancer agent - An Hsp90 inhibitor (17-AAG)
    Waza, Masahiro
    Adachi, Hiroaki
    Katsuno, Masahisa
    Minamiyama, Makoto
    Tanaka, Fumiaki
    Sobue, Gen
    INTEGRATED MOLECULAR MEDICINE FOR NEURONAL AND NEOPLASTIC DISORDERS, 2006, 1086 : 21 - 34
  • [7] Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment
    Talaei, Sona
    Mellatyar, Hassan
    Asadi, Asadollah
    Akbarzadeh, Abolfazl
    Sheervalilou, Roghayeh
    Zarghami, Nosratollah
    CHEMICAL BIOLOGY & DRUG DESIGN, 2019, 93 (05) : 760 - 786
  • [8] Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Kadia, Tapan M.
    Borthakur, Gautam
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Daver, Naval Guastad
    Pemmaraju, Naveen
    Jabbour, Elias
    Estrov, Zeev
    Ramachandran, Abhijit
    Paradela, Jamil
    Pond, Blake
    Ravandi, Farhad
    Vusirikala, Madhuri
    Patel, Prapti Arvind
    Levis, Mark J.
    Perl, Alexander E.
    Andreeff, Michael
    Collins, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [9] Cancer cells harboring MET gene amplification are sensitive to Hsp90 inhibitor 17-AAG
    Wang, Suiquan
    Tsutsumi, Shinji
    Xu, Wanping
    Neckers, Len
    CANCER RESEARCH, 2009, 69
  • [10] BCL2A1: A Novel Target in Refractory/Relapsed AML with FLT3-ITD/D835 Double Mutations
    Yamatani, Kotoko
    Carter, Bing Z.
    Konopleva, Marina
    Tabe, Yoko
    Andreeff, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S286 - S287
12345